During the years of the economic boom, many public funds were
allocated to research in the health sector with the sole
requirement that it would generate knowledge and that said
knowledge would appear in relatively prestigious publications,
ensuring doctors and researchers that they would remain eligible
for funding. In general, this knowledge resembled a
"gift" to the scientific and medical community, with the
goal of "continuing to move forward". In other words,
scientific publications were the tool used to make funding come
full circle and to continue to take on projects and receive public
funds. Yet despite this, hospitals and their corresponding research
centres experienced many difficulties in transforming the
innovations they generated into products and services that directly
The economic crisis has brought about the need to reconsider
this funding model due to two major reasons: the cut in public
funds, which has caused publications in prestigious magazines to no
longer come full circle and ensure the continuity of funding; and
the growing need to increase the positive impact of research
carried out in hospitals and in their research centres on
Clearly there is no single solution that solves all of the
above, yet over the past few years there appears to be an effective
solution that consists of bringing the world of business closer to
hospitals and their research centres. As a result, businesses
benefit from the innovations generated directly by hospitals, and
hospitals, in turn, thrive from funding in this context. These
hospitals can then follow different lines of research, generate new
ones and ensure that the results of their research and innovation
lead to new and improved products and services for patients.
This is where patents play and should play a key role, since
they are one of the instruments that allow the new paradigm to
work. Patents are a crucial connecting link between hospitals and
businesses for several reasons. For businesses, they are a type of
guarantee ensuring that a return on their investment can be
obtained through the monopoly granted. In addition, if the patent
has already been examined by one of the "strong" offices
(European, United States or Japan Patent Office), it has certain
guarantees with respect to the innovative aspect of the invention.
On the other hand, from the point of view of hospitals, patents
represent the embodiment of innovations generated in hospitals,
thus supporting their value and the transfer of knowledge.
Therefore, patents, in my opinion, are a key tool to once again
help research funding in hospitals and in their research centres
come full circle. And as a result, if patent knowledge and
development is properly encouraged, giving them an important role
in health research, they can be called upon to play a very
important role both in changing the paradigm in the hospital sector
as well as in transforming the economy into a knowledge
En 45 minutos haremos un rápido repaso de todas las novedades relevantes que, en el mundo de la Propiedad Industrial e Intelectual, se han producido durante en el transcurso del 2016, junto a nuestra previsión de los principales hitos que nos depara este nuevo año.
Queremos que los temas propuestos sean sólo aquéllos que más les interesen. A tal fin, hemos incluido los siguientes a partir de las consultas recibidas durante este año. No obstante, estaríamos encantados de contar con sus sugerencias.
La participación de la autoridad mexicana en materia de Propiedad Industrial es crucial durante la tramitación del Registro Sanitario de un medicamento alopático.
Cada etapa del proceso de Registro Sanitario tiene directrices bien establecidas; sin embargo, las etapas que se relacionan con los derechos de Propiedad Intelectual continúan causando controversia.
Con el fin de entender la relación entre los derechos de Propiedad Intelectual y el proceso de Registro Sanitario, Clarke Modet & Cº ofrece una amplia variedad de soluciones desde el punto de vista de Propiedad Intelectual.
1.The trade mark shall not entitle the proprietor to prohibit its use in relation to goods which have been put on the market in the Community under that trade mark by the proprietor or with his consent.
The UK government has not yet invoked Article 50 of the Treaty on European Union (this is likely to happen by the end of March), and the UK's actual exit from the European Union is at least two years away.
Without doubt Malta offers significant opportunities for the generics drugs Industry and the
evidence for this lies in the pharmaceutical patenting history of the country and in its legislative
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).